Reglan Tardive Dyskinesia Settlement: Washington Reglan Tardive Dyskinesia Injury Lawyer

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Targeted Risk Awareness

For decades, general health and science information has served as the foundation for public understanding of medication risks and benefits. This broad educational context has enabled individuals to make informed decisions about treatments ranging from common ailments to complex conditions. Within this legacy framework, the focus remained on overall wellness and the balance between therapeutic efficacy and potential side effects. As medical knowledge advanced, attention increasingly turned to specific adverse outcomes associated with long-term medication use. One such area of concern involves exposure to certain drugs that affect neurological function. In particular, the medication Reglan (metoclopramide) has been linked to a serious movement disorder known as tardive dyskinesia, which can develop after prolonged use. This condition, characterized by involuntary repetitive movements, represents a significant shift from general health education to targeted risk awareness. The transition from broad health information to occupational exposure concern arises when considering populations with sustained access to Reglan, such as healthcare workers or patients requiring extended treatment. For those in occupational settings, the risk of tardive dyskinesia becomes a practical matter of workplace safety and long-term health monitoring. This pivot underscores the need for specialized legal and medical guidance, particularly in jurisdictions like Washington where settlement options exist for affected individuals. The focus now narrows from general awareness to actionable steps for those facing real-world consequences of medication exposure.

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat conditions such as gastroesophageal reflux and diabetic gastroparesis. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning underscores the need for clinicians to use Reglan for the shortest duration necessary and to periodically reassess the need for continued therapy. For patients with symptomatic gastroesophageal reflux, the maximum recommended treatment duration is 12 weeks, and for diabetic gastroparesis, treatment should also be limited to 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD signs is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and may persist even after Reglan is discontinued. The condition arises from the drug's mechanism of action: metoclopramide blocks dopamine D2 receptors in the brain, which can lead to extrapyramidal side effects, including TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). While TD is often associated with long-term use, cases have been reported after even a single dose of metoclopramide, as seen in a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration (https://pubmed.ncbi.nlm.nih.gov/34712535/). This highlights that TD can occur with minimal exposure, particularly in individuals with underlying risk factors.

Clinical Presentation and Diagnosis of Tardive Dyskinesia

The clinical presentation of TD can vary, but it typically involves orofacial movements such as lip smacking, grimacing, or tongue protrusion. Diagnosis is based on clinical observation and a history of exposure to dopamine-blocking agents like Reglan. The FDA label warns that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Therefore, clinicians should be vigilant for early symptoms and immediately discontinue Reglan if TD is suspected. From a medicolegal perspective, the adequacy of warnings regarding Reglan and TD is a critical issue. The FDA's boxed warning explicitly states that Reglan is contraindicated in patients with a history of TD and that treatment should be stopped if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, liability may arise if healthcare providers fail to inform patients of the risks or if pharmaceutical companies are found to have provided inadequate warnings. A medicolegal article notes that physicians face liability when they have knowledge of adverse effects but do not adequately communicate them to patients, and it also discusses circumstances under which pharmaceutical companies may be held liable for side effects such as TD (https://pubmed.ncbi.nlm.nih.gov/31356297/). This suggests that both prescribing clinicians and manufacturers may be subject to legal action if warnings are insufficient or if patients are not properly monitored.

Legal Considerations and Settlement Options in Washington

For affected patients in Washington, settlement-related considerations are important. The timeline between exposure to Reglan and documented harm can vary widely. While TD typically develops after months or years of use, cases like the single-dose incident demonstrate that harm can occur rapidly (https://pubmed.ncbi.nlm.nih.gov/34712535/). Patients who develop TD may pursue legal claims based on failure to warn, negligence, or product liability. Settlements often depend on factors such as the severity of the movement disorder, the duration of Reglan use, and whether the patient was adequately informed of the risks. Given the potentially irreversible nature of TD, compensation may cover medical expenses, lost wages, and pain and suffering. In summary, Reglan use is associated with a well-documented risk of tardive dyskinesia, as highlighted by FDA warnings and clinical evidence. The risk increases with longer treatment duration and higher cumulative doses, but even short-term exposure can trigger TD in susceptible individuals. Adequate warnings are crucial for informed consent, and failure to provide them may lead to liability. Patients in Washington who have developed TD after Reglan use should consider consulting a legal professional to explore settlement options, given the serious and often permanent nature of the condition.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Reglan and why is it associated with tardive dyskinesia?

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat gastroesophageal reflux and diabetic gastroparesis. It is associated with tardive dyskinesia (TD) because blocking dopamine receptors can lead to extrapyramidal side effects, including involuntary movements. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the symptoms of tardive dyskinesia caused by Reglan?

Symptoms include involuntary, repetitive movements of the face, tongue, trunk, or extremities, such as lip smacking, grimacing, or tongue protrusion. These movements can be disfiguring and may persist even after stopping Reglan (https://pubmed.ncbi.nlm.nih.gov/34712535/).

Can tardive dyskinesia occur after short-term use of Reglan?

Yes, although TD typically develops after months or years of use, cases have been reported after a single dose of metoclopramide, as documented in a postoperative patient (https://pubmed.ncbi.nlm.nih.gov/34712535/).

What legal options are available for Washington residents who developed TD from Reglan?

Washington residents may pursue claims based on failure to warn, negligence, or product liability. Settlements may cover medical expenses, lost wages, and pain and suffering. Consulting a legal professional is recommended to explore options (https://pubmed.ncbi.nlm.nih.gov/31356297/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.